Back to Search
Start Over
Characteristics of Patients Newly Prescribed IDegLira in U.S. Real-World Practice
- Source :
- Diabetes. 67
- Publication Year :
- 2018
- Publisher :
- American Diabetes Association, 2018.
-
Abstract
- Background: IDegLira, a fixed-ratio combination of a basal insulin (BI), insulin degludec, and liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1), was approved by the FDA in Q4 2016 for the treatment of type 2 diabetes Mellitus (T2DM). This study describes characteristics of adult patients (pts) who initiated IDegLira in a real-world setting. Methods: Demographic and clinical data for pts prescribed IDegLira between May and November 2017 were extracted from the Practice Fusion ambulatory care database. Pt characteristics were described for the 6-months prior to initiation. Pts were grouped by most recent antidiabetic therapy regimen in the prior 6-months. Results: Pts prescribed IDegLira (n=388) received one of five prior therapy regimens: BI as only injectable (BI-INJ, N=88), GLP-1 as only injectable (GLP-INJ, N=47), GLP-1+insulin (GLP-INS, N=65), multiple daily insulin injections (MDI, N=35), and no injectable therapy (N-INJ, N=153). On average, IDegLira pts were 58 years old (SD 11.5); the majority (66%) between 40 and 64 years of age. Pts’ mean BMI was 35 (7.6). Mean A1C was 9.0 (1.82), with 12% below 9%. The N-INJ group had the highest mean A1C prior to initiating IDegLira (9.6), BI-INJ and GLP-INJ had intermediate means (both 9.0), and the GLP-INS and MDI groups had the lowest (8.4, 8.3). IDegLira patients previously treated with GLP-INS, MDI, and N-INJ had higher Charlson Comorbidity and Diabetes Complication Severity scores compared to patients previously treated with BI-INJ or GLP-INJ. Most prescriptions were written by PCPs (53%). Conclusion: This analysis shows that initial use of IDegLira has been across a range of practices and clinical profiles. Most IDegLira prescribing occurred among pts on a previous injectable therapy, with those on single injectable therapy having higher A1Cs than those on multiple injectable therapies. Pts prescribed IDegLira with no injectable therapy in the prior 6 months had the highest A1C values. Disclosure M. Mocarski: Employee; Self; Novo Nordisk Inc.. Stock/Shareholder; Self; Novo Nordisk A/S. J. da Rocha Fernandes: Employee; Self; Novo Nordisk A/S, International Diabetes Federation. L. Kallenbach: None. J. Vasey: None. J. Ken: None. A.N. Bogdanov: None. M. Radin: Employee; Self; Novo Nordisk Inc. L.E. Egede: Research Support; Self; National Institute of Diabetes and Digestive and Kidney Diseases. Advisory Panel; Self; Novo Nordisk Inc..
- Subjects :
- Insulin degludec
medicine.medical_specialty
Liraglutide
business.industry
Endocrinology, Diabetes and Metabolism
Insulin
medicine.medical_treatment
Type 2 Diabetes Mellitus
medicine.disease
Comorbidity
Regimen
Ambulatory care
Diabetes mellitus
Internal medicine
Internal Medicine
medicine
business
medicine.drug
Subjects
Details
- ISSN :
- 1939327X and 00121797
- Volume :
- 67
- Database :
- OpenAIRE
- Journal :
- Diabetes
- Accession number :
- edsair.doi...........f3ba9108d2ce9cd5dce53eb1697150b4